The manipulation of networks such as the co-inhibitory PD-1–PD-L1 pathway and suppressor IL-10–IL-10R pathway could be an attractive and novel immunotherapeutic intervention for AML patients ineligible for standard treatment with chemotherapy and hematopoietic stem cell transplantation. Here, IL10RA is linked to acute myeloid leukemia.